$ 174,130$ 72,216$ 398,585$ 185,583(1)
Net sales for the three and nine months ended September 30, 2012 reported by Jazz Pharmaceuticals plc include net sales from the historic Azur Pharma business for the period from July 1, 2012 through September 30, 2012 and from January 18, 2012 through September 30, 2012, respectively, and net sales from the historic EUSA Pharma business for the period from July 1, 2012 through September 30, 2012 and from June 12, 2012 through September 30, 2012, respectively.
Net sales from women's health products are included in discontinued operations.The following unaudited pro forma information represents the combined net product sales for the three and nine months ended September 30, 2012 and 2011, respectively, as if the merger with Azur Pharma, the acquisition of EUSA Pharma and disposition of the women's health business had each been completed on January 1, 2011:SUMMARY OF PRODUCT SALES, NET (PRO FORMA) (In thousands) (Unaudited)Three Months Ended September 30,Nine Months Ended September 30,2012201120122011Xyrem
$ 102,615$ 62,547$ 265,149$ 161,503Erwinaze/Erwinase
13,41812,32238,70839,935Total pro forma net sales
$ 174,130$ 109,195$ 481,015$ 293,584JAZZ PHARMACEUTICALS PLCCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited) September 30,December 31,20122011ASSETSCurrent assets:Cash and cash equivalents
$ 189,793$ 82,076Marketable securities
7,1271,690Other current assets
9,9421,260Assets held for sale
59,546-Total current assets
385,012199,131Property and equipment, net
|SOURCE Jazz Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved